Bayesian Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$10.8M |
| 2 |
Microsoft
MSFT
|
+$7.69M |
| 3 |
TSMC
TSM
|
+$6.92M |
| 4 |
AbbVie
ABBV
|
+$6.78M |
| 5 |
NKLA
Nikola Corporation Common Stock
NKLA
|
+$6.58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$49.3M |
| 2 |
Biogen
BIIB
|
+$6.69M |
| 3 |
Accenture
ACN
|
+$6.42M |
| 4 |
Target
TGT
|
+$5.14M |
| 5 |
Walt Disney
DIS
|
+$4.08M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.52% |
| 2 | Consumer Discretionary | 16.31% |
| 3 | Healthcare | 16% |
| 4 | Industrials | 8.7% |
| 5 | Financials | 8.37% |
Similar funds
Bayesian Capital Management's Q3 2020 Portfolio in Review
As of Q3 2020, Bayesian Capital Management held 781 positions worth $409M, down 9.7% from $453M the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Bayesian Capital Management withdrew a net $59.6M in Q3 2020, closing 283 positions and reducing 120 holdings. Its most notable exit was Biogen, an estimated $6.69M position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 21% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Bayesian Capital Management opened a new position in Apple worth $11.5M.
- Bayesian Capital Management's largest Q3 2020 buy was Apple: 99,200 shares worth $11.5M.
- Bayesian Capital Management added most to Microsoft in Q3 2020, an estimated $7.69M increase.
- Bayesian Capital Management's biggest Q3 2020 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $49.3M.
- Bayesian Capital Management fully exited Biogen in Q3 2020, selling an estimated $6.69M.
- Bayesian Capital Management's ten largest holdings make up 18% of its $409M portfolio in Q3 2020.
- Bayesian Capital Management opened 279 new positions and closed 283 in Q3 2020.
- Bayesian Capital Management's portfolio value fell 9.7% quarter-over-quarter to $409M.
Based on Bayesian Capital Management's 13F filing for Q3 2020, filed 12 Nov 2020.